Industry Insights Healthcare: 18/07/25
In this week’s insights post, we discuss three of the most recent advancements and hot topics in the healthcare industry.
Bringing sun exposure-related risks to light
As UV (ultraviolet) Safety Awareness Month takes centre stage, healthcare professionals have once again reminded the public of the critical importance of sun safety. Excessive sun exposure remains a leading cause of skin cancer, including melanoma — the deadliest type. Experts emphasised protection strategies such as using sunscreen, wearing protective clothing and limiting exposure during peak sunlight hours. Awareness efforts aim to reduce the incidence of skin damage and associated health risks.
Link to Skin and Cancer Institute article
Semaglutide may be linked to lower dementia risk in type 2 diabetes
Semaglutide, a medication commonly used to manage type 2 diabetes, has shown promise in decreasing dementia risk in this patient group. A recent study published in the Journal of Alzheimer’s Disease found that patients treated with semaglutide exhibited a lower risk of dementia when compared to those receiving other antidiabetic medications. The study analysed patient electronic health records (EHRs) in the US of 1,710,995 eligible patients living with diabetes. According to the researcher, the drug’s benefits may stem from improved glycaemic control and reduction of cardiovascular risk factors, both strongly associated factors with cognitive decline.
What’s the deal with artificial sweeteners?
Artificial sweeteners like aspartame or sucralose are often marketed as healthy alternatives to sugar. However, their impact on health is an ongoing debate. Recent studies underscore their dual nature: while these sweeteners help reduce calorie intake and manage blood sugar levels, they may also negatively affect gut health and metabolism. Researchers have linked artificial sweeteners to an increased risk of cancer, increased insulin resistance and diabetes risk and a higher risk of obesity, amongst other effects. Although regulatory agencies consider these substances ‘safe within approved limits’, studies have underscored the importance of cautious consumption for public health and economic costs.
Links to studies:
Want to get in touch? Contact us at https://elion.nz/get-in-touch/
